The interest of the investor in the appearance of biotechnology, and the financing reaches 268 million dollars in 2024 after a decline: a report

Omnivore, one of the leading sustainability capital companies in India, has released a report entitled “End entitled” “Investment report at India Life Sciences- Five-year Review“ In partnership with the nucleus. It was revealed during the BIOWAVE event at C-CAMP in Bangalore, and the report offers a deep diving in the scene of biotechnology financing in India from 2020 to 2024.

The report reveals that the biotechnology sector in India has gained remarkable momentum with an investment of $ 1.9 billion through 465 deals over a five -year period – a clear indication of capital flows towards creating biotechnology. Peak financing was recorded at $ 749 million in 2022, followed by a slowdown with disruption investments to $ 269 million in 2024.

Biowave, an initiative by omnivore, Nucleate and Indiebio, is designed to enhance investment and innovation in the biological economy in India. With the support of BIRAC, C-CAMP, IKP, Bangalore Bioinnovation, Venture Center and Sine (Iit Bombay), the platform seeks to highlight the work of business scientists throughout the country.

Biomedia and medical technology dominated the financing scene, which represents 42 % of the total investments. However, the investor’s interest rises in emerging sectors such as sustainable and new materials (7 %), agricultural life sciences (10 %), industrial biotechnology (10 %), biomed and informational services (31 %).

Geographical, Bangaluru, Delhi-Nen, Mumbai and Chennai attracted 90 % of the total investment. However, medium -level cities such as Pion, Hyderabad and Ahmedabad appear as promising biotechnology centers.

The seed phase deals reached their climax in 2021 with 77 rounds, but they decreased to 62 in 2024, reflecting the caution of the investor towards pre -rent projects. While the series A remained consistent, the Series B to $ 253 million increased in 2022 before declining to $ 48 million in 2024.

“This report provides decisive visions on this transformation – where the pricing is the flow of capital and how it is quick to prepare for the investor with deep technology through industrial biotechnology and sustainable materials,” said Mark Khan, the administrative partner of Omnivore. “To eliminate India’s capabilities truly in climate work, resource efficiency, and food security, the continuous flow of capital to startups led by biological sciences will be necessary.”

The vital economy in India doubled more than twice, increasing from $ 86 billion in 2020 to $ 165.7 billion in 2024 – after now contributed 4.25 % to national GDP. While startups in biotechnology remains a small part of the ecosystem, they play a vital role in leading innovation through agriculture, manufacturing and health care.

“Biowave is an important landmark in the scene of Indian biotechnology by combining incubators, adventure capitalists and stakeholders in the ecosystem,” said Dr. Gityndra Kumar, Berke Managing Director, Biotechnology Department. “DBT-BIRC has constantly defended biological innovation, and I welcome new change makers in this task. This strategic cooperation creates the necessary basis for raising the ecosystems of life sciences in India worldwide. The report clearly shows the diversification of promising investment beyond traditional biological drugs to sustainable materials and more clear technology with our national innovation.”

“The C-CAMP, in cooperation with omnivore and Nucleate, added in this initiative. Bioave creates critical links between scientific innovation and a focus on the growing smell in the next generation of our repetition of repetition of repetition in repetition to repetition. Innovation centers. Regional across India.

While investments in the early stage faced the opposite wind, the report notes a steady rise in institutional investors, VCS for companies, and global climate funds that support biotechnology projects. To completely realize the capabilities of the sector, it calls for the continuous flow of capital to both early and leading companies that lead the biological economy of India.